JIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting

Bulletin Express

03/25

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The decision follows feedback from certain shareholders requesting additional time to evaluate the scheme. Management indicated that the share award programme is neither essential nor time-sensitive at this stage.

As a direct consequence of the withdrawal, the extraordinary general meeting (EGM) originally slated for 8 April 2026 at 14:30 in Hangzhou has been cancelled. The company issued an apology to shareholders for any inconvenience caused.

The board currently comprises two executive directors (Mr. Fu Hang, Mr. Zhou Wei), four non-executive directors (Mr. Wu Shihang, Mr. Albert Esteve Cruella, Mr. Fei Junjie, Ms. Yan Weiting) and three independent non-executive directors (Mr. Zhou Zhihui, Ms. Ho Mei Yi, Dr. Zhou Demin).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1164747939"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164747939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164747939?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164747939","market":"us","top_or_hot":-1,"title":"JIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The decision follows feedback from certain shareholders requesting additional time to evaluate the scheme. Management indicated that the share award programme is neither essential nor time-sensitive at this stage.</p>\n<p>As a direct consequence of the withdrawal, the extraordinary general meeting (EGM) originally slated for 8 April 2026 at 14:30 in Hangzhou has been cancelled. The company issued an apology to shareholders for any inconvenience caused.</p>\n<p>The board currently comprises two executive directors (Mr. Fu Hang, Mr. Zhou Wei), four non-executive directors (Mr. Wu Shihang, Mr. Albert Esteve Cruella, Mr. Fei Junjie, Ms. Yan Weiting) and three independent non-executive directors (Mr. Zhou Zhihui, Ms. Ho Mei Yi, Dr. Zhou Demin).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIUYUAN GENE Withdraws 2026 Share Award Scheme Resolutions and Cancels 8 Apr Extraordinary General Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-25 12:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The decision follows feedback from certain shareholders requesting additional time to evaluate the scheme. Management indicated that the share award programme is neither essential nor time-sensitive at this stage.</p>\n<p>As a direct consequence of the withdrawal, the extraordinary general meeting (EGM) originally slated for 8 April 2026 at 14:30 in Hangzhou has been cancelled. The company issued an apology to shareholders for any inconvenience caused.</p>\n<p>The board currently comprises two executive directors (Mr. Fu Hang, Mr. Zhou Wei), four non-executive directors (Mr. Wu Shihang, Mr. Albert Esteve Cruella, Mr. Fei Junjie, Ms. Yan Weiting) and three independent non-executive directors (Mr. Zhou Zhihui, Ms. Ho Mei Yi, Dr. Zhou Demin).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1164747939","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164747939","pubTimestamp":1774412486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"久远基因撤回2026年股份奖励计划决议案并取消4月8日临时股东大会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (JIUYUAN GENE) announced on 25 March 2026 that its board has withdrawn all resolutions related to the proposed 2026 Share Award Scheme. The decision follows feedback from certain shareholders requesting additional time to evaluate the scheme. Management indicated that the share award programme is neither essential nor time-sensitive at this stage.\nAs a direct consequence of the withdrawal, the extraordinary general meeting (EGM) originally slated for 8 April 2026 at 14:30 in Hangzhou has been cancelled. The company issued an apology to shareholders for any inconvenience caused.\nThe board currently comprises two executive directors (Mr. Fu Hang, Mr. Zhou Wei), four non-executive directors (Mr. Wu Shihang, Mr. Albert Esteve Cruella, Mr. Fei Junjie, Ms. Yan Weiting) and three independent non-executive directors (Mr. Zhou Zhihui, Ms. Ho Mei Yi, Dr. Zhou Demin).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}